217 related articles for article (PubMed ID: 34930156)
1. Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.
Tanous O; Azulay Y; Halevy R; Dujovny T; Swartz N; Colodner R; Koren A; Levin C
BMC Nephrol; 2021 Dec; 22(1):418. PubMed ID: 34930156
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
Ricchi P; Meloni A; Pistoia L; Gamberini MR; Cuccia L; Allò M; Putti MC; Spasiano A; Rosso R; Cecinati V; Righi R; Renne S; Peritore G; Vallone A; Positano V; Quaia E; Cademartiri F; Pepe A
Blood Transfus; 2024 Jan; 22(1):75-85. PubMed ID: 37146300
[TBL] [Abstract][Full Text] [Related]
4. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
5. Effects on hearing after long-term use of iron chelators in beta-thalassemia: Over twenty years of longitudinal follow-up.
Aldè M; Ambrosetti U; Giuditta M; Cassinerio E; Piatti G
Auris Nasus Larynx; 2024 Apr; 51(2):271-275. PubMed ID: 37903661
[TBL] [Abstract][Full Text] [Related]
6. The effects of chelators on zinc levels in patients with thalassemia major.
Erdoğan E; Canatan D; Ormeci AR; Vural H; Aylak F
J Trace Elem Med Biol; 2013 Apr; 27(2):109-11. PubMed ID: 23164519
[TBL] [Abstract][Full Text] [Related]
7. Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
Takpradit C; Viprakasit V; Narkbunnam N; Vathana N; Phuakpet K; Pongtanakul B; Sanpakit K; Buaboonnam J
Pediatr Int; 2021 Apr; 63(4):404-409. PubMed ID: 32856363
[TBL] [Abstract][Full Text] [Related]
8. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Ladis V; Chouliaras G; Berdoukas V; Moraitis P; Zannikos K; Berdoussi E; Kattamis C
Eur J Haematol; 2010 Oct; 85(4):335-44. PubMed ID: 20561034
[TBL] [Abstract][Full Text] [Related]
9. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with β-thalassemia major.
Al-Khabori M; Bhandari S; Al-Rasadi K; Mevada S; Al-Dhuhli H; Al-Kemyani N; Daar S
Hemoglobin; 2014; 38(5):365-8. PubMed ID: 25074643
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.
Tripathy I; Panja A; Dolai TK; Mallick AK
Hemoglobin; 2021 Sep; 45(5):296-302. PubMed ID: 34758688
[TBL] [Abstract][Full Text] [Related]
13. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
Luangasanatip N; Chaiyakunapruk N; Upakdee N; Wong P
Clin Drug Investig; 2011; 31(7):493-505. PubMed ID: 21627338
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
Xia S; Zhang W; Huang L; Jiang H
PLoS One; 2013; 8(12):e82662. PubMed ID: 24376563
[TBL] [Abstract][Full Text] [Related]
15. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
16. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
Pepe A; Meloni A; Rossi G; Cuccia L; D'Ascola GD; Santodirocco M; Cianciulli P; Caruso V; Romeo MA; Filosa A; Pitrolo L; Putti MC; Peluso A; Campisi S; Missere M; Midiri M; Gulino L; Positano V; Lombardi M; Ricchi P
J Cardiovasc Magn Reson; 2013 Jan; 15(1):1. PubMed ID: 23324167
[TBL] [Abstract][Full Text] [Related]
17. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
[TBL] [Abstract][Full Text] [Related]
18. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
[TBL] [Abstract][Full Text] [Related]
19. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
